Scholarlink

<p>Invariant NKT (iNKT) cells have a T-cell receptor that is common to all individuals and are activated by recognizing glycolipids on MHC class I-like CD1d molecules. Activated iNKT cells are known to exert anti-tumor effects through the activation of other immune cells and have attracted attention as promising T cells for eliciting anti-tumor immunity. However, securing a sufficient number of iNKT cells is an obstacle to treatment because iNKT cells are a very small cell population, less than 0.1% of the peripheral blood lymphocytes. Although previous studies have demonstrated redifferentiation of a large number of CD4<sup>–</sup>CD8<sup>–</sup> double-negative iNKT cells from induced pluripotent stem (iPS) cells in two-dimensional monolayer cultures, CD4<sup>+</sup> single-positive (CD4SP) iNKT cells could not be induced. Here we show CD4SP iNKT cells can be obtained by three-dimensional (3D) organoid culture (3D-CD4+ iNKT cell). We additionally describe 3D-CD4+ iNKT cells show antigen-specific helper functions, as they proliferate, produce interferon-γ/interleukin-4 (IFN-γ/IL-4), and induce dendritic cell maturation in response to α-galactosylceramide. Furthermore, they reverse the inhibition of T cell proliferation induced by immunosuppressive macrophages in an antigen-specific manner. Collectively, 3D-CD4+ iNKT cells may become an adjuvant T-cell source to enhance current T-cell immunotherapy against solid tumors.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Artificial thymic organoid culture generates functional iPSC-derived CD4+ invariant natural killer T cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月9日

查看全文
  • Sara Shiina,
  • Tatsuki Ueda,
  • Shoichi Iriguchi,
  • Yasushi Uemura,
  • Shin Kaneko

摘要

Invariant NKT (iNKT) cells have a T-cell receptor that is common to all individuals and are activated by recognizing glycolipids on MHC class I-like CD1d molecules. Activated iNKT cells are known to exert anti-tumor effects through the activation of other immune cells and have attracted attention as promising T cells for eliciting anti-tumor immunity. However, securing a sufficient number of iNKT cells is an obstacle to treatment because iNKT cells are a very small cell population, less than 0.1% of the peripheral blood lymphocytes. Although previous studies have demonstrated redifferentiation of a large number of CD4–CD8– double-negative iNKT cells from induced pluripotent stem (iPS) cells in two-dimensional monolayer cultures, CD4+ single-positive (CD4SP) iNKT cells could not be induced. Here we show CD4SP iNKT cells can be obtained by three-dimensional (3D) organoid culture (3D-CD4+ iNKT cell). We additionally describe 3D-CD4+ iNKT cells show antigen-specific helper functions, as they proliferate, produce interferon-γ/interleukin-4 (IFN-γ/IL-4), and induce dendritic cell maturation in response to α-galactosylceramide. Furthermore, they reverse the inhibition of T cell proliferation induced by immunosuppressive macrophages in an antigen-specific manner. Collectively, 3D-CD4+ iNKT cells may become an adjuvant T-cell source to enhance current T-cell immunotherapy against solid tumors.